Show simple item record

dc.contributor.authorMcGowan, P M
dc.contributor.authorMullooly, M
dc.contributor.authorCaiazza, F
dc.contributor.authorSukor, S
dc.contributor.authorMadden, S F
dc.contributor.authorMaguire, A A
dc.contributor.authorPierce, A
dc.contributor.authorMcDermott, E W
dc.contributor.authorCrown, J
dc.contributor.authorO'Donovan, N
dc.contributor.authorDuffy, M J
dc.date.accessioned2014-08-05T15:01:03Z
dc.date.available2014-08-05T15:01:03Z
dc.date.issued2013-02
dc.identifier.citationMcGowan PM et al. ADAM-17: a novel therapeutic target for triple negative breast cancer. Ann. Oncol. 2013, 24 (2):362-9en_GB
dc.identifier.issn1569-8041
dc.identifier.pmid22967992
dc.identifier.doi10.1093/annonc/mds279
dc.identifier.urihttp://hdl.handle.net/10147/324259
dc.description.abstractValidated targeted therapy is currently unavailable for patients with invasive breast cancer negative for oestrogen receptors, progesterone receptors and HER2 [i.e., those with triple-negative (TN) disease]. ADAM-17 is a protease involved in the activations of several ligands that bind to and promotes intracellular signalling from the EGFR/HER family of receptors.
dc.language.isoenen
dc.rightsArchived with thanks to Annals of oncology : official journal of the European Society for Medical Oncology / ESMOen_GB
dc.subjectBREAST CANCERen_GB
dc.subject.meshADAM Proteins
dc.subject.meshBreast Neoplasms
dc.subject.meshCell Line, Tumor
dc.subject.meshCell Proliferation
dc.subject.meshCell Survival
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMolecular Targeted Therapy
dc.subject.meshPhosphorylation
dc.subject.meshRNA, Messenger
dc.subject.meshReceptor, Epidermal Growth Factor
dc.subject.meshReceptor, erbB-2
dc.subject.meshReceptors, Estrogen
dc.subject.meshReceptors, Progesterone
dc.subject.meshSignal Transduction
dc.subject.meshTransforming Growth Factor alpha
dc.subject.otherCELL BIOLOGYen_GB
dc.titleADAM-17: a novel therapeutic target for triple negative breast cancer.en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Pathology and Laboratory Medicine, St Vincent's University Hospital, Dublin, Ireland. patricia.mcgowan@ucd.ieen_GB
dc.identifier.journalAnnals of oncology : official journal of the European Society for Medical Oncology / ESMOen_GB
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen
html.description.abstractValidated targeted therapy is currently unavailable for patients with invasive breast cancer negative for oestrogen receptors, progesterone receptors and HER2 [i.e., those with triple-negative (TN) disease]. ADAM-17 is a protease involved in the activations of several ligands that bind to and promotes intracellular signalling from the EGFR/HER family of receptors.


This item appears in the following Collection(s)

Show simple item record